Literature DB >> 26676407

The Clinical Utility of TIMP3 Expression in ACTH-Secreting Pituitary Tumor.

Bowen Sun1, Xiaohai Liu1, Yakun Yang1, Congxin Dai1, Ying Li2, Yonghui Jiao1, Zhenqing Wei1, Yong Yao1, Ming Feng1, Xinjie Bao1, Kan Deng1, Ning Wang2, Renzhi Wang3.   

Abstract

In recent years, the tissue inhibitor of metalloproteinase-3 (TIMP3) plays a pivotal role in tumorigenesis, while the role of TIMP3 in adrenocorticotrophic hormone (ACTH)-secreting pituitary adenomas remains unclear. In this study, 86 sporadic pituitary tumor specimens, including ACTH (40), GH (18), PRL-secreting (8), and non-functioining (20) and non-tumorous pituitary samples (n = 10) were available, and then, the mRNA and protein expression of TIMP3 was quantified by quantitative reverse transcriptase polymerase chain reaction (RT-PCR), western blotting, and immunohistochemistry, respectively. Our findings showed that TIMP3 expression was significantly correlated with Ki-67 expression and the invasiveness of pituitary adenomas. TIMP3 mRNA and protein expression were reduced in ACTH-secreting pituitary adenomas and the other three types of pituitary adenomas compared to adjacent non-tumorous pituitary tissues (all p < .01). On the other hand, the expression of TIMP3 was negatively correlated with tumor size and Ki-67 in ACTH-secreting pituitary adenomas. TIMP3 mRNA expression was significantly lower in invasive pituitary adenomas than that in noninvasive ones (1.92-fold, p < .05). TIMP3 protein levels were also significantly lower in the majority of invasive adenomas (1.41-fold, p < .05) Furthermore, TIMP3 mRNA and protein expression were significantly lower in pituitary giant adenomas than those in microadenomas (2.58-fold, p < .05). In conclusion, the expression of TIMP3 is low in pituitary adenomas including ACTH-secreting pituitary adenomas and negatively associated with tumor aggressiveness. TIMPs may play a potential role in the progression of ACTH-secreting pituitary adenomas and be useful as a biomarker of invasiveness.

Entities:  

Keywords:  ACTH-secreting pituitary tumor; Clinicopathology; Ki-67; TIMP3

Mesh:

Substances:

Year:  2015        PMID: 26676407     DOI: 10.1007/s12031-015-0698-z

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  24 in total

1.  Matrix metalloproteinases and their inhibitors in human pituitary tumors.

Authors:  E Beaulieu; Z Kachra; N Mousseau; L Delbecchi; J Hardy; R Béliveau
Journal:  Neurosurgery       Date:  1999-12       Impact factor: 4.654

2.  The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932.

Authors:  H Cushing
Journal:  Obes Res       Date:  1994-09

3.  Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin-dependent Cushing's syndrome prior to transsphenoidal surgery.

Authors:  Sigrid Jehle; Jane E Walsh; Pamela U Freda; Kalmon D Post
Journal:  J Clin Endocrinol Metab       Date:  2008-09-16       Impact factor: 5.958

4.  Heterogeneous epigenetic regulation of TIMP3 in prostate cancer.

Authors:  Toshiaki Shinojima; Qiang Yu; Sharon K Huang; Michelle Li; Ryuichi Mizuno; Edison T Liu; Dave S B Hoon; Laurent Lessard
Journal:  Epigenetics       Date:  2012-09-28       Impact factor: 4.528

5.  Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis.

Authors:  S Jane Darnton; Laura J Hardie; Ronald S Muc; Christopher P Wild; Alan G Casson
Journal:  Int J Cancer       Date:  2005-06-20       Impact factor: 7.396

6.  Transsphenoidal microsurgery for Cushing disease. A report of 216 cases.

Authors:  T J Mampalam; J B Tyrrell; C B Wilson
Journal:  Ann Intern Med       Date:  1988-09-15       Impact factor: 25.391

7.  Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Authors:  Yonatan Y Mahller; Sachin S Vaikunth; Maria C Ripberger; William H Baird; Yoshinaga Saeki; Jose A Cancelas; Timothy M Crombleholme; Timothy P Cripe
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

8.  Tissue inhibitor of metalloproteinase-3 (TIMP-3) regulates hematopoiesis and bone formation in vivo.

Authors:  Yi Shen; Ingrid G Winkler; Valerie Barbier; Natalie A Sims; Jean Hendy; Jean-Pierre Lévesque
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

9.  A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family.

Authors:  N Pavloff; P W Staskus; N S Kishnani; S P Hawkes
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

10.  Methylation of TIMP3 in esophageal squamous cell carcinoma.

Authors:  Eric Smith; Neville J De Young; Zi-Qiang Tian; Maria Caruso; Andrew R Ruszkiewicz; Jun-Feng Liu; Glyn G Jamieson; Paul A Drew
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

View more
  3 in total

1.  MicroRNA-30d target TIMP3 induces pituitary tumor cell growth and invasion.

Authors:  Bowen Sun; Congxin Dai; Shangfeng Zhao; Hao Dong; Haocheng Liu; Yong Li; Renzhi Wang; Jun Kang
Journal:  Gland Surg       Date:  2021-12

2.  Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma.

Authors:  Brigita Glebauskiene; Rasa Liutkeviciene; Alvita Vilkeviciute; Inga Gudinaviciene; Aurelija Rocyte; Dovile Simonaviciute; Ruta Mazetyte; Loresa Kriauciuniene; Dalia Zaliuniene
Journal:  Biomed Res Int       Date:  2018-05-31       Impact factor: 3.411

Review 3.  Molecular Network Basis of Invasive Pituitary Adenoma: A Review.

Authors:  Qi Yang; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-24       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.